Asset 1

Biotech

We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.

With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.

Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.

We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.

Sciences de la vie et Santé

Edison Open House Global Healthcare 2021 – key takeaways from our panel

4 février 2021
Quick read

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Will the UK government's COVID-19 dosing regime gamble pay off?

11 janvier 2021
Briefing

par Alison Dennis et Justyna Ostrowska

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session

6 janvier 2021
Quick read

par Adrian Toutoungi

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021

3 décembre 2020
Briefing

par Alison Dennis et Paul England, DPhil

Cliquer ici pour en savoir plus

Événements connexes